银屑病作为系统性疾病的管理:证据是什么?
本叙述性综述总结生物制剂改善银屑病患者系统性炎症后果的已发表证据,探讨银屑病与其常见共病之间的病理生理关系,并讨论中重度银屑病需要包含减轻系统性炎症策略的新治疗范式。现有证据提示,早期使用生物制剂可能预防炎症相关损伤及共病发展,甚至可能逆转现有炎症损伤。
要点
- 银屑病是系统性免疫介导疾病,与银屑病关节炎、心血管病、糖尿病、肥胖、炎症性肠病和非酒精性脂肪肝风险增加相关。
- 中重度斑块状银屑病早期使用生物制剂可能预防炎症损伤和共病发展。
- 近期研究提示逆转现有炎症损伤和改善炎症共病症状也可能实现。
核心结论
- 现有证据提示,对中重度斑块状银屑病患者早期使用生物制剂,预防炎症相关损伤及未来炎症损伤和共病发展可能是可实现的治疗目标。
- 近期研究令人鼓舞的数据提示,逆转现有炎症损伤和改善炎症共病体征与症状这一更高目标也可能实现。
研究设计与样本
- 本文件为叙述性综述,总结已发表的关于生物制剂改善银屑病患者系统性炎症后果能力的证据。
主要发现
- 银屑病发病由促炎细胞因子驱动,并与银屑病关节炎、心血管疾病、糖尿病、肥胖、炎症性肠病和非酒精性脂肪肝等共病风险增加相关。
- 当前证据提示,早期使用生物制剂可能预防炎症相关损伤及未来炎症损伤和共病发展。
- 近期研究提示,逆转现有炎症损伤和改善炎症共病症状也可能实现。
临床怎么用
- 对中重度斑块状银屑病患者,可考虑早期使用生物制剂以减轻系统性炎症并预防共病。
局限性
- 正在进行的前瞻性研究关于生物制剂对银屑病患者系统性炎症标志物影响的结果,将加强用于指导中重度银屑病治疗决策的临床证据基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic and often painful skin plaques. Psoriasis pathogenesis is driven by proinflammatory cytokines and psoriasis is associated with increased risk for comorbidities, including, but not limited to, psoriatic arthritis, cardiovascular disease, diabetes mellitus, obesity, inflammatory bowel disease and nonalcoholic fatty liver disease compared with the general population. OBJECTIVES: To explore the pathophysiological relationship between psoriasis and its common comorbidities and discuss the need for new treatment paradigms that include strategies to reduce systemic inflammation in patients with moderate-to-severe psoriasis. METHODS: This narrative review summarizes the published evidence related to the ability of biological therapies to ameliorate the consequences of systemic inflammation in patients with psoriasis. RESULTS: Current evidence suggests that preventing damage associated with inflammation, and preventing development of future inflammatory damage and comorbidities, may be a potentially achievable treatment goal for many patients with moderate-to-severe plaque psoriasis when biological therapies are utilized early in the disease. Encouraging data from recent studies suggest that the loftier goal of reversing existing inflammatory damage and improving signs and symptoms of inflammatory comorbidities could also possibly be attainable. CONCLUSIONS: Results from ongoing prospective studies regarding the effects of biologics on markers of systemic inflammation in patients with psoriasis will strengthen the clinical evidence base that can be used to inform treatment decisions for patients with moderate-to-severe psoriasis. What's already known about this topic? Psoriasis is a systemic inflammatory disease and treatments are needed to optimize patient outcomes. What does this study add? This review discusses new psoriasis treatment paradigms that may potentially reduce effects of systemic inflammation. Evidence demonstrating that biological treatment may prevent or reverse inflammatory damage associated with psoriasis comorbidities is reviewed.
引用
- Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2019. PMID: 31225638. doi:10.1111/bjd.18245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。